• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. CRISPR-Cas9 Mediated Efficient PD-1 Disruption on Mouse T Cells for Colorectal Cancer Treament in vi

CRISPR-Cas9 Mediated Efficient PD-1 Disruption on Mouse T Cells for Colorectal Cancer Treament in vi

来源 :2016第九届世界癌症大会 | 被引量 : 0次 | 上传用户：atom1999
【摘 要】
：
Programmed cell death protein 1/programmed death ligands 1(PD-1/PD-L1) is a critical for modulating immune responses to cancer.A new class of monoclonal antibodies that block PD-1/PD-L1 immune checkpo
【作 者】
：
Jian Dong 
【机 构】
：
The Third Affiliated Hospital of Kunming Medical University China
【出 处】
：
2016第九届世界癌症大会
【发表日期】
：
2016年7期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　Programmed cell death protein 1/programmed death ligands 1(PD-1/PD-L1) is a critical for modulating immune responses to cancer.A new class of monoclonal antibodies that block PD-1/PD-L1 immune checkpoint signal,activate the immune system to attack tumors and are therefore used with varying success to treat some types of cancer.
其他文献
The Role of Breast Cancer Index Test in Early Hormone-positive Breast Cancer Management
Extended adjuvant endocrine therapy (10 vs.5 years) trials have demonstrated improved outcomes in early-stage estrogen receptor (ER)-positive breast cancer;however,the absolute benefit is modest,and t
会议
Breast Cancer Burden and Disparities Among Underserved Women: Lessons from a Community-based Partici
Breast cancer is the most common cancer in women worldwide and second leading cause of deaths among women in the United States.
会议
Cryoablation of the Primary Breast Cancer in Patients with Stage Ⅳ of Disease
Metastatic breast cancer is considered an incurable disease,and the main treatment goal is palliation,with the aim of maintaining or improving the quality of life and possibly improving survival.
会议
Oncolytic HSV-1 Virus with Multiple Regulatory Mechanisms for Specific Tumour Targeting
Oncolytic virus therapy (OVs) has recently emerged as a promising antitumor therapeutics mainly due to selectively replicate in tumor cells while sparing normal cells.
会议
Effectivity of Long Antigen Exposition Dendritic Cell Therapy (Lanex-DC(R)) in the Adjuvant Treatmen
We analyzed the outcome of immunotherapy in the additional adjuvant treatment of rectal cancer with dendritic cell therapy.Patients (n=71) who underwent curative surgery for rectal cancer were include
会议
Metabolic Communication and Competition: How T Cells Fight and Cooperate in Tumors
Metabolic transformation is a cardinal hallmark of most cancer cells that increases their proliferative and anti-apoptotic capacity by boosting anabolic metabolism,mainly through aerobic glycolysis an
会议
Therapeutic Potentials of Cancer Biologics and Vaccines
Cancer Therapeutics exploits the subtle differences one can find between cancer and normal cells to fight off cancer.These differences can be present on their cell surfaces,and such biomarkers can be
会议
Immuno-targeting ENO1 as a Novel Strategy for Cancer Therapy
Alpha-Enolase (ENO 1) is a catalytic enzyme participating in the penultimate step of glycolysis and also poses several non-metabolic functions such as plasminogen-binding.
会议
Metastatic Gastrointestinal Cancers: Is Immunotherapy a Real Hope?
Gastrointestinal (GI) cancers are the most common human malignancies in the world.Surgical resection continues being the primary curative treatment for most of them.
会议
Immunotherapy in Lung Cancer: Dawn of a New Era!
Modulation of a patients immune system so that it acts against lung cancer cells has not been successful in the past decades.Advances in our understanding of the immune response to tumors resulted in
会议